Kornimate/medical-research-clean huggingface dataset:
mechanical thrombectomy of acute occlusion in ischemic stroke

Conditions: Acute Stroke

Summary: assessment of therapeutic benefits and hazards of mechanical thrombectomy in ischemic stroke patients with proximal occlusion within 4.5 hours from stroke onset.

stroke is an acute neurologic dysfunction of vascular origin with sudden or at least rapid occurrence of symptoms and signs corresponding to the involvement of focal areas in the brain.the two main types of stroke are ischemic and hemorrhagic.thrombosis can form in the extracranial and intracranial arteries when the intima is roughened and plaque forms along the injured vessel.the endothelial injury permits platelets to adhere and aggregate, then coagulation is activated and thrombus develops at site of plaque.blood flow through the extracranial and intracranial systems decreases, and the collateral circulation maintains function. when the compensatory mechanism of collateral circulation fails, perfusion is compromised, leading to decreased perfusion and cell death. stroke is the third leading cause of death in the united states. many people die each year from stroke in the united states.stroke is the leading cause of serious, long-term disability in the united states. nearly one fourth of strokes occur in people under the age of 65.high blood pressure is the most important risk factor for stroke. intravenous recombinant tissue-type plasminogen activator is the only food and drug administration approved treatment for acute ischemic stroke. mechanical thrombectomy improves clinical outcomes in patients with acute ischemic stroke caused by a large vessel occlusion.there is no apparent benefit of intravenous thrombolysis to patients with ischemic stroke undergoing mechanical thrombectomy. the study will be performed involving ischemic stroke patients with proximal occlusion within 4.5 hours from stroke onset.

Eligibility criteria:
inclusion criteria: 1. aged between 18 - 80 years old of both sex. 2. acute ischemic stroke due to proved large-artery occlusion. 3. ineligibility for iv thrombolysis. 4. a timeframe of ≤ 4.5 hours between stroke onset and the start of mechanical thrombectomy. 5. the patients included in this series should have an nihss score of at least 10 or fluctuating symptoms. 6. aspects of 6 or \> 6 7. all patients will be undergoing ct/ct angiography before and after treatment exclusion criteria: 1. age older than 80 years or less than 18 2. cerebral haemorrhage. 3. acute infarction \> 1/3 of middle cerebral artery (mca) territory on ct-scan. 4. a history of stroke in the last 6 weeks. 5. a time interval of \> 4.5 hours. 6. laboratory evidence of coagulation abnormalities. 7. known arteriovenous malformation , neoplasm or aneurysm. 8. woman at child bearing age who has a positive pregnancy test
gender differences in robotic surgery for rectal cancer: a retrospective study

Conditions: Rectal Cancer; Gender; Complication,Postoperative; Surgery-Complications

Summary: objective: to investigate gender-based differences in outcomes following robotic surgery for rectal cancer. methods: a retrospective study was conducted on 155 patients (82 males, 73 females) who underwent robotic surgery for rectal cancer. demographic, pre-operative, operative, and post-operative data were collected and analyzed. pre-operative study: all patients underwent a standardized pre-operative work-up, which included a physical examination, comprehensive colonoscopy with biopsy, rigid rectoscopy, pelvic magnetic resonance imaging (mri) scan, computed tomography (ct) of the thorax and abdomen, and measurement of carcinoembryonic antigen (cea) levels. tumor staging followed the tnm staging criteria (american joint committee on cancer), with the t and n stages determined by the most advanced findings from any imaging modality data collected: retrospective evaluation and comparison of demographic characteristics, pre-operative tnm stage, distance from anal verge, tumor size, tumor grade, american society of anesthesiologists (asa) score, and body mass index (bmi) were conducted among both patient groups. peri-operative and post-operative data, including morbidity and mortality, were assessed, alongside parameters such as distal resection margin (drm), proximal resection margin (prm), harvested lymph nodes (hln), and clavien-dindo classification (cdc) scores. diagnosis of anastomotic leakage was confirmed by clinical suspicion (e.g., changes in drainage, fever, abdominal pain) and further validated through contrast enema observed during follow-up computed tomography (ct). hospital stay and readmission rates were monitored for up to 90 days post-surgery. post-operative follow-up: post-operative outcomes encompassed operative duration, estimated blood loss, time to first flatus passage, duration of liquid diet, and length of hospital stay following surgery. operative duration comprised the time from initial skin incision to closure, including the time needed for robotic surgery docking and undocking. upon experiencing initial flatulence, patients transitioned to a liquid diet. hospital stay duration was measured from the time of surgery to discharge. the overall cost of surgery, including surgical procedures, anesthesia, medications, and post-operative care, was considered in the total expenditure analysis.


Eligibility criteria:
inclusion criteria: a confirmed histological diagnosis of colorectal malignancy was a prerequisite for enrollment in this study. additionally, obtaining informed consent from patients for surgical intervention was mandatory. exclusion criteria: patients with bleeding of the gastrointestinal tract, inflammatory bowel disease, synchronous tumors, benign conditions, and clinical t4 stage tumors unresponsive to neoadjuvant therapy were excluded from the study.
monteleukast versus inhaled mometasone for treatment of otitis media with effusion in children

Conditions: Otitis Media With Effiusion

Summary: otitis media is one of the most common infections among children and is a complication in about 30% of common colds. the most common complication of acute otitis media is otitis media with effusion. some studies have reported the effects of montelukast and mometasone nasal spray in treatment of otitis media with effusion. however, current information is inadequate in this issue. the aim of this study was to compare the effectiveness of montelukast and mometasone nasal spray in treatment of otitis media with effusion in children attending koodakan hospital in bandar abbas, iran.


Eligibility criteria:
inclusion criteria: * • children who were between 2 to 6 years old * definite diagnosis of ome with symptoms and examination exclusion criteria: * • currently were using corticosteroids or prophylactic monteleukast * chronic pulmonary or cardiac diseases or immune deficiency * allergic rhinitis * hypersensitivity to monteleukast or corticosteroids * avoidance of parents to fill the written informed consent
comparison of ba-duan-jin and pregabalin in patients with fibromyalgia

Conditions: Fibromyalgia

Summary: fibromyalgia is a chronic debilitating musculoskeletal pain syndrome. pregabalin is the only medication that has been approved to treat fibromyalgia in china. currently, there has been a growing interest in the development of non-pharmacological therapies. ba-duan-jin is an ancient chinese exercise for health promotion yet easy to learn. findings from our previous study showed an effectiveness and good safety of ba-duan-jin in patients with fibromyalgia. this study is to evaluate the effectiveness comparison of ba-duan-jin and pregabalin in managing fibromyalgia symptoms experienced by chinese patients.


Eligibility criteria:
inclusion criteria: * meet the 1990 american college of rheumatology (acr) research classification criteria for fibromyalgia; * be between the ages of 18 to 70 years. exclusion criteria: * had practiced ba-duan-jin, tai chi, yoga or other forms of qigong exercise within 12 months of their recruitment to the study; * be less than 40mm of pain vas score; * had renal failure, and severe depression or anxiety; * had any poorly-controlled comorbid medical conditions, such as dementia, cancer, thyroid disease, inflammatory arthritis; * pregnancy or planned pregnancy within the study period; * patients residing more than 70 miles from the research site.

Keywords: eight brocades; ba-duan-jin; baduanjin; qigong; pain
an observational cohort study to investigate the risk of thromboembolic events in patients receiving kcentra® or plasma to reverse vitamin k antagonist (vka) therapy in the setting of acute major bleeding

Conditions: Hemorrhage

Summary: this observational cohort study is designed to obtain product safety information from the routine clinical setting within large, diverse, community-based populations. in the setting of acute major bleeding in which patients are treated for vitamin k antagonist reversal, the risk of thromboembolic events (tee) in patients treated with kcentra® and in patients treated with plasma will be assessed.


Eligibility criteria:
inclusion criteria: * aged 18 years and older at admission for vka-associated major bleeding * a minimum of 365 days of continuous health plan enrollment before the index hospitalization involving acute vka reversal treatment * a minimum of 365 days of continuous pharmacy benefit before the index hospitalization involving acute vka reversal treatment exclusion criteria: patients will be excluded from the primary analyses if they: * require urgent reversal of vka therapy in the setting of bleeding due to major trauma (eg, motor vehicle accident) * requiring urgent reversal of vka therapy for a surgical procedure unrelated to major bleeding (eg, appendicitis)

Keywords: vitamin k reversal antagonist therapy of acute major bleeding warfarin reversal
effect of pyridorin in patients with diabetic nephropathy

Conditions: Diabetic Nephropathy

Summary: the primary objective of the study is to evaluate the safety and tolerability of pyridorin (pyridoxamine dihydrochloride) 50 mg given orally twice daily in patients with diabetic kidney disease.


Eligibility criteria:
inclusion criteria: * males and females (non-pregnant and non-lactating) between 18 and 70 years of age with type 1 or type 2 diabetes * sitting blood pressure of \<=170/100 mm hg at weeks -2 and -1 * hemoglobin a1c \<=12% at week -2 * patients with diagnosis of diabetic nephropathy as defined by 1. serum creatinine \<=2.0 mg/dl at weeks -2 and -1 2. urinary albumin excretion \>=300 mg/24 hours at week -2 3. diagnosis of diabetic retinopathy * creatinine clearance \>=40 ml/min at weeks -2 and -1 * voluntary written consent to participate in this study exclusion criteria: * history of allergic or adverse response to any b vitamin * history of major cardiovascular or cerebrovascular events * history of cancer except adequately treated basal or squamous cell carcinoma of the skin * history of diabetic ketoacidosis

Keywords: diabetic nephropathy advanced glycation endproduct inhibitor pyridorin pyridoxamine
sexual functioning study with antidepressants

Conditions: Depressive Disorder, Major; Major Depressive Disorder (MDD)

Summary: effects of two depression medication on sexual functioning

a twelve-week, multi-center, randomized, double-blind, double-dummy, parallel-group, active controlled, escalating dose study to compare the effects on sexual functioning of bupropion hydrochloride extended-release (wellbutrin xl, 150-450 mg/day) and extended-release venlafaxine (effexor xr, 75-225 mg/day) in subjects with major depressive disorder

Eligibility criteria:
inclusion criteria: * primary diagnosis of major depressive disorder (mdd) * must have met dsm-iv criteria for current major depressive episode for at least 8 weeks but no long than 2 years. * ham-d17 total score of \>17 at screening and baseline. * severity of illness score of \>4 at screening and baseline. * willing to discuss sexual functioning with investigator or designee. * sexual activity that leads to orgasm at least every 2 weeks. exclusion criteria: * past or current dsm-iv diagnosis of bipolar disorder i or ii, schizophrenia or another psychotic disorder(s). * primary dsm-iv diagnosis or received treatment for panic disorder, obsessive compulsive disorder or post stress disorder within previous 12 months. * poses a homicidal or serious suicidal risk, have made an attempt within months prior to screening or who has ever been homicidal. * myocardial infarction with 1 year of screening. * taken ibupropion hydrochloride or venlafaxine in the last 6 months. * positive urine test for illicit drug use or alcohol or substance abuse within the past 12 months. * psychotherapy within 3 months. * pregnant. * electroconvulsive therapy or transcranial magnetic stimulation within 6 months prior of screening. * ecg or clinical evidence of atrial or ventricular hypertrophy.

Keywords: sexual dysfunction depression mdd
dining with diabetes in pennsylvania

Conditions: Diabetes Mellitus, Type 2

Summary: penn state extension's dining with diabetes program is an evidence-based community education program for people with or at risk for type 2 diabetes. the program teaches participants how to prevent or manage their disease by providing practical knowledge and strategies to make the necessary lifestyle changes that will lead to healthier living and reduction in the risk of complications. the overall goals and objectives of the program are as follows: increasing knowledge of healthy food choices for families with or at risk for diabetes promoting behavior changes by offering demonstrations and tasting of healthy food. increasing knowledge of essential medical tests associated with diabetes management. promoting physical activity as a component of diabetes control. encouraging self-management and self-efficacy skill. connecting participants to their healthcare providers for long-term follow-up. the program is designed to meet 4 consecutive weeks and then a 3 month follow-up. participants a1c and blood pressure are taking at the first and follow-up classes. classes consist of a nutrition lesson, physical activity, cooking demonstration and food tasting.


Eligibility criteria:
inclusion criteria: * individuals with type 2 diabetes individuals with pre-diabetes individuals at risk of developing type 2 diabetes healthy family members/caretakers healthy volunteers exclusion criteria: * under age 18
radiofrequency ablation for recurrent hepatocellular carcinoma with twin cooled-wet electrodes

Conditions: Hepatocellular Carcinoma; Local Recurrence of Malignant Tumor of Liver

Summary: to investigate the therapeutic effects and treatment results of radiofrequency ablation using combined bipolar and monopolar energy deliver with twin cooled-wet electrodes for recurrent tumor after locoregional treatment in patients with hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: * child-pugh class a or b * chronic hepatitis b or chronic hepatitis c or liver cirrhosis * presence of recurrent hepatocellular carcinoma (hcc) after locoregional treatment confirmed by pathology or imaging studies including contrast enhanced computed tomography (ct) or magnetic resonance imaging (mri) according to liver imaging reporting and data system (li-rads) v2018 * single lesion less than or equal to 5 cm, or up to 3 lesions, each greater than less than or equal to 3 cm at the time of locoregional treatment exclusion criteria: * number of recurrent hccs, equal or more than 3 * largest recurrent hcc size over 3 cm * presence of vascular invasion by hcc * platelet count less than 40,000 per mm3 or international normalized ratio (inr) prolongation over 50% * presence of extrahepatic metastasis
colistin pharmacokinetics in continuous renal replacement therapy

Conditions: Infection

Summary: the blood concentration of the antibiotic colistin is determined in patients in whom kidney function is reduced such that a renal replacement therapy is needed. hypothesis:no dose reduction is needed in patients undergoing continuous renal replacement therapy over 24h because colistin is sufficiently removed by this procedure.

after administration of intravenous colistin multiple blood samples are drawn over one dosing interval on day 1, 3, and 5 of treatment. patients are monitored for signs of neuro- and nephrotoxicity

Eligibility criteria:
inclusion criteria: * male or female aged 18 years or older * hospitalised on the icu * gram-negative infection requiring antibiotic therapy with intravenous colistin as part of their routine medical care * clinical necessity for continuous venovenous renal replacement therapy exclusion criteria: * history of hypersensitivity to colistin or to other polymyxins * personal or family history of myasthenia gravis

Keywords: pharmacokinetics antibiotic gram negative continuous renal replacement therapy
one-piece hydrophobic acrylic intraocular lens in subjects undergoing cataract extraction

Conditions: Aphakia; Cataract

Summary: the objective of this study is to evaluate the safety and effectiveness of the envista® one-piece hydrophobic acrylic intraocular lens (iol), following primary implantation for the visual correction of aphakia in adults 18 years of age or older in whom the cataractous lens has been removed by an extracapsular cataract extraction method (eg, small incision phacoemulsification).


Eligibility criteria:
inclusion criteria: * subjects must have a clinically documented diagnosis of age-related cataract that is considered amenable to treatment with standard phacoemulsification/extracapsular cataract extraction. * subjects must have a best corrected visual acuity (bcva) equal to or worse than 20/40 in the study eye, with or without a glare source. * subjects must have a bcva projected to be better than 20/30 after iol implantation in the study eye. exclusion criteria: * subjects with any anterior segment pathology for which extracapsular phacoemulsification cataract surgery would be contraindicated. * subjects with any other serious ocular pathology, or underlying serious medical conditions, which based on the investigator's medical judgment, could confound the results of the study.

Keywords: ocular surgery phacoemulsification
scholar performance and praxis assessment in children with rolandic epilepsy

Conditions: Rolandic Epilepsy; Apraxia

Summary: rolandic epilepsy is the most common form of childhood epilepsy. it is classified as idiopathic, age-related epilepsy syndrome with benign evolution. the absence of neuropsychological impairment is part of the criteria of benignity of this epilepsy syndrome. however recently have been suggested several deficits related to attention and language. the purpose of this study was assess school performance and to investigate problems of praxis in patients with rolandic epilepsy as compared to a control group composed of normal children with age, gender and educational level equivalents.

method: nineteen patients aged between 7 and 12 years underwent clinical neurological evaluation, psychological assessment, through weschsler scales of intelligence and language evaluation, to assess the academic performance and research of the presence or absence of praxis difficulties.

Eligibility criteria:
inclusion criteria: * diagnosis of rolandic epilepsy using clinical, eeg and neuroimaging findings * patients had neurological, ophthalmic and auditory unchanged, and intelligence quotient (iq) equal to or above 80. * all parents signed the consent form, authorizing the participation of their children (as) in the search. exclusion criteria: * with oral language and writing of the following tables, whereas the dsm-iv: pervasive developmental disorders, cerebral palsy child acquired aphasia, hearing impairment (including mild conductive hearing loss), progressive disease * what not signed the consent form.

Keywords: epilepsy language childhood praxis
acute changes in endothelial function in germ cell tumor patients treated with cisplatin and untreated germ cell tumor controls

Conditions: Germ Cell Cancer

Summary: cisplatin is one of the most common chemotherapy drugs used to treat many different cancers, including germ cell tumors (gct). cisplatin is very effective in treating gct, but there are side effects. one of the possible long-term side effects of cisplatin is thought to be heart disease. the way that cisplatin causes heart disease is not well understood. one possibility is that cisplatin may damage the inside layer of blood vessels called the endothelium. the purpose of this study is to measure changes in the endothelium that happen when patients with gct get cisplatin chemotherapy and to compare these changes with a group of patients not receiving chemotherapy.


Eligibility criteria:
inclusion criteria: cisplatin-based chemotherapy group * histologically-proven diagnosis of gct * male * age ≥18 * no prior exposure to chemotherapy or radiation * planned to receive 3-4 cycles of cisplatin-based chemotherapy surgery-only group * histologically-proven diagnosis of gct male * age ≥18 * surgical management of gct performed less than 90 days before start of study (includes orchiectomy and primary retroperitoneal lymph node dissection (rplnd)) * no prior exposure to chemotherapy or radiation exclusion criteria: cisplatin-based chemotherapy group * prior exposure to chemotherapy or radiation * known diagnosis or history of being diagnosed with vasculitis, autonomic dysfunction, coronary artery disease, or collagen-vascular disease surgery-only group * prior exposure to chemotherapy or radiation * planned for non-surgical management with chemotherapy or radiation. * known diagnosis or history of being diagnosed with vasculitis, autonomic dysfunction, coronary artery disease, or collagen-vascular disease.

Keywords: endothelial function endo-pat2000 system 11-140